{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Testosterone xt"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K201908",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122793"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "September 15, 2020",
    "Summary Letter Received Date": "September 18, 2020",
    "Submission Date": "July 02, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae Testosterone xt chemiluminescent immunoassay for quantitative testosterone determination in serum and EDTA plasma",
    "Indications for Use Summary": "Quantitative determination of testosterone in human serum and EDTA plasma for diagnosis and treatment of disorders involving male sex hormones, including hypogonadism, puberty disorders, impotence in males, and hirsutism/virilization in females, on the LIAISON\u00ae XL Analyzer",
    "fda_folder": "Clinical Chemistry"
}